Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

First implantation of Crux's vena cava filter

This article was originally published in Clinica

Executive Summary

The Crux inferior vena cava (IVC) filter developed by Crux Biomedical, of Portola Valley, California, has been implanted in the first patient. The retrievable device is designed to prevent pulmonary emboli (PE). It was implanted as part of a pivotal IDE study, which is being conducted at 12 institutions in the US. Retrievable IVC filters can be left inside the patient on a permanent basis, or may be removed via minimally-invasive methods once the patient is no longer at risk for a PE. Annual sales of IVC filters in the US are estimated to reach $252m in 2008.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049938

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel